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Abstract: Disorders of sex development (DSD) are a group of rare conditions that usually 
present with atypical genitalia in the newborn period or as delayed puberty in an adolescent. 
Although a concern about the development of external genitalia may exist in one in 300 newborn 
infants, discrete genetic conditions that underlie DSD are generally rarely identified. It is likely 
that this diagnostic gap exists for a number of reasons and these include an inadequate knowl-
edge of the pathogenesis and underlying mechanisms that lead to DSD, variation in assessment 
and in-depth phenotyping of these rare conditions, inadequate availability of quality accredited 
laboratories and, lastly, limited awareness of the value of a molecular genetic diagnosis for 
improving short-term and long-term care of the affected person.
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Introduction to the management issues  
in disorders of sex development (DSD)
DSD are a group of rare conditions that are generally characterized by an abnormal-
ity of the chromosomal, gonadal or phenotypic features that typically define sex 
 development. Such conditions usually present with atypical genitalia in the newborn 
period or as delayed puberty in an adolescent. Although truly ambiguous genitalia 
on expert examination are relatively rare, reported to occur in about 1:4,500 births,1 
a concern about the development of the external genitalia may, however, exist in one 
in 300 newborn infants.2 Discrete genetic conditions that underlie DSD are gener-
ally rarely identified. For instance, congenital adrenal hyperplasia (CAH) due to 
21-hydroxylase deficiency, which is the commonest cause of 46,XX DSD, has an 
approximate incidence of one in 10,000 to one in 14,000 in all infants. Whilst over 
95% of cases of 46,XX DSD are due to this condition, the likelihood of identifying 
a discrete genetic condition in cases of 46,XY DSD is, at best, 50%.3 It is likely that 
this diagnostic gap exists for a number of reasons and these include an inadequate 
knowledge of the pathogenesis and underlying mechanisms that lead to DSD, variation 
in assessment and in-depth phenotyping of these rare conditions, inadequate avail-
ability of quality accredited laboratories and, lastly, limited awareness of the value 
of a molecular genetic diagnosis for improving short-term and long-term care of the 
affected person. Besides narrowing the diagnostic gap, the other challenges that face 
genetics include the development of a cost effective and efficient method of processing 
large scale genetic data in such a way that not only does it benefit individual patients 
in explaining inter-individual disease variation but it can also be integrated with other 
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rapidly developing technologies (including transcriptomics, 
proteomics, and metabolomics as well as novel methods of 
targeted phenotyping such as cellular and organ imaging), so 
that the pathology as well as the management of each person 
with a DSD can be understood at an individual level.
The review is subdivided into four main sections: the first 
section covers the pathway of the genetic control and the 
pathophysiology of sex development as well as the current 
classification of DSD and the initial diagnostic investigations. 
Emphasis is placed on the advances in genetic and genomic 
technologies for the clinical diagnosis and on the ethical 
challenges in management. The final section covers the future 
directions in the field of DSD, including the modern aspects 
of electronic media and communication, the networks of 
clinical and research expertise and the necessity for them to 
extend and include a wider community of scientists.
Pathogenesis of DSD
DSD are a group of heterogeneous conditions with diverse 
pathophysiology.4 There are many factors involved in the 
differentiation of the sex organs into male or female, result-
ing in a diverse clinical phenotype (Figure 1).
The urogenital ridge, the common precursor of the uri-
nary and genital systems, develops at approximately 4 weeks 
post-fertilization in the human embryo as a thickening of the 
mesodermic mesonephros covered by coelomic epithelium.3 
Several genes including NR5A1, WT1, EMX2, CBX2 and 
PBX1 are required for formation of the bipotential gonadal 
ridge. At 7 weeks, in the XY gonad, SRY is expressed in 
 pre-Sertoli cells resulting in the upregulation of SOX9 expres-
sion that is further augmented by the synergistic action of 
SRY and NR5A1, leading to the initiation of definitive Sertoli 
cell differentiation.5,6 The transcriptional activation by SRY 
and NR5A1 is mediated by the binding of these two proteins 
to the testis-specific enhancer of SOX9 core (TESCO) region, 
which lies approximately 13 kb upstream of SOX9.7 Once 
SOX9 levels reach a critical threshold, several positive regu-
latory loops are initiated, including autoregulation of SOX9 
expression and formation of feed-forward loops via FGF9 
or PGD2 signaling.5,6 During testicular development, SOX9 
functions, by regulating the production of AMH from Sertoli 
cells, and possibly by repressing genes involved in ovarian 
development such as WNT4 and FOXL2.6,8,9 The DMRT1 
transcription factor may also be involved in this process.3
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Figure 1 A summary of the critical molecular and genetic events in mammalian sex determination and differentiation.
Abbreviation: DHT, 5-dihydrotestosterone.
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Once formed, Sertoli cells induce the development 
of fetal Leydig cells, via a hedgehog-signaling pathway, 
which at 8–9 weeks of development produces androgens 
and INSL3.10 Testosterone and AMH cause regression of 
 Müllerian structures and differentiation of the Wolffian duct 
into the epididymis, vas deferens, and seminal vesicles, 
whereas INSL3 is required for testicular descent. In 46,XY 
males, testosterone is converted to 5-dihydrotestosterone 
(DHT) by the enzyme 5-AR, resulting in the development 
of male external genitalia.11,12 The activity of DHT is medi-
ated by the nuclear transcription factor, AR, which has high 
affinity for DHT.
In the XX gonad, the absence of SRY, resulting in the 
inability of SOX9 expression to reach a critical threshold, 
together with the expression of factors such as RSPO1/WNT4 
signaling, FST and FOXL2 lead to formation of the ovary, 
at least in part through suppression of the activity of “testis” 
genes.8,9 In the 46,XX female, the Wolffian duct regresses 
and the Müllerian duct is maintained and forms the oviduct, 
uterus, cervix, and upper part of the vagina. The absence of 
androgens leads to the development of female genitalia.
The use of genomic analyses in recent years (including, 
for example, high-resolution single nucleotide polymor-
phism [SNP] array with copy-number estimation using 
Robust Multichip Analysis), has led to the identification 
of genomic alterations affecting several of the genes that 
participate in the control of gonadal development and to 
the delineation of their transcriptional regulatory regions. 
For instance, genomic rearrangements (such as duplication 
and triplication) affecting SOX9 regulatory elements, located 
significantly further upstream (.500 kb) than the TESCO 
enhancer region, were found in patients with 46,XX sex 
reversal.13–15
In addition, genomic rearrangements affecting the regula-
tory region of SOX3, and leading to its increased or ectopic 
expression, were detected in three people with 46,XX sex 
reversal.16 The X chromosomal SOX3 gene, believed to be 
the ancestor of the SRY gene, is not normally expressed in the 
developing gonad. Therefore, when ectopically expressed, it 
might substitute for SRY in driving testicular development.7 
In addition, a probable regulatory element lying downstream 
of the GATA4 gene was identified when a 35 kb deletion 
was detected in a person with 46,XY complete gonadal 
 dysgenesis.17 Similarly, in those with 46,XY DSD, microar-
ray analysis detected an intragenic deletion of WWOX18 and a 
deletion at least 42 kb upstream of the DMRT1 gene.19 In fact, 
array analyses have now identified many DNA duplications 
and deletions in people with DSD, several of which are located 
close to known sex development genes and are suspected to 
have caused disruption of gene regulatory regions.7
It is clear, therefore, that there is potential for disruption 
of the sex organ differentiation process at multiple different 
stages. The clinical phenotype will depend on the nature of 
disruption.
Classification of DSD
The current system for the classification of DSD was intro-
duced in the Chicago Consensus in 2005.20 There are three 
broad groups: sex chromosome DSD, 46,XX DSD, and 
46,XY DSD.
Sex chromosome DSD
Sex chromosome DSD includes conditions such as 47,XXY 
(Klinefelter syndrome and variants), 45,X (Turner syndrome 
and variants), 45,X/46,XY (mixed gonadal dysgenesis) and 
46,XX/46,XY (chimerism). These are often identified ante-
natally, frequently as an incidental finding, with confirmation 
of the diagnosis after birth.21 Antenatal diagnosis allows for 
focused evaluation of the other complications often associ-
ated with these disorders, for example, cardiac anomalies in 
Turner syndrome. It also provides the opportunity to offer 
counselling to families prior to the birth.
46,XX DSD
46,XX DSD encompasses disorders of gonadal develop-
ment, such as gonadal dysgenesis and disorders secondary 
to androgen excess. Androgen excess during pregnancy 
may be endogenous (secondary to an adrenal adenoma, der-
moid cyst, Sertoli-Leydig tumor, sex cord stromal tumor or 
metastatic carcinoma) or exogenous (secondary to danazol, 
progestins or potassium sparing diuretics).22 Exogenous ste-
roids taken during pregnancy can also cause posterior fusion 
of the labia, clitoral enlargement, and increased degrees of 
androgenization.23
The commonest known genetic condition that leads to 
46,XX DSD is CAH due to 21α-hydroxylase deficiency 
and this occurs in approximately one in 10,000 to one in 
14,000 infants.24 Rarer conditions include 46,XX testicular 
DSD which refers to a male with testes and male genitalia, 
and 46,XX ovotesticular DSD which refers to individuals that 
have both ovarian and testicular tissue in the gonads, usually 
as ovotestes, but less commonly as separate gonads.
46,XY DSD
46,XY DSD has three broad categories: disorders of gonadal 
development, disorders in androgen synthesis or action and 
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other causes, including hypogonadotropic hypogonadism, 
cryptorchidism, and isolated hypospadias. Girls with 46,XY 
DSD will most likely have androgen insensitivity syndrome 
(AIS), gonadal dysgenesis or a biochemical disorder of 
androgen synthesis.
Diagnosis
Initial investigations should include a thorough history 
and clinical examination of the infant. Clinical examina-
tion should not simply focus on the external genitalia, but 
also seek to determine if there are any dysmorphic features 
or evidence of further developmental anomalies. Careful 
inspection and palpation of the external genitalia should 
then be undertaken, with the aid of scoring systems, such 
as the external masculinization score for a more objective 
approach.25
After initial examination, f irst line investigations 
should include a karyotype, ultrasound examination 
for Müllerian structures, and serum levels of AMH and 
 17-hydroxyprogesterone. Ideally, results of these tests should 
be available within 48 hours to allow for sex assignment as 
early as possible.26 Additional investigations should include 
serum testosterone, cortisol, androstenedione, gonadotropins, 
and urinalysis. Serial measurements of urea and electrolytes 
are useful, in order to identify cases of CAH with salt wast-
ing, although this may present later. The requirements for 
further investigations will be guided by the results of these 
initial tests.4
Advances in genetic  
and genomic technologies  
for clinical diagnosis of DSD
Genetic testing is recognized as a key element in the inves-
tigation of individuals with a suspected DSD.26 Molecular 
diagnosis is useful in the management of DSD, potentially 
providing information about long-term fertility, adrenal 
health, and germ-line tumor risk as well as an understanding 
of the etiology and recurrence risks for affected individuals 
and their parents.
The first line investigation of a possible DSD includes 
quantitative fluorescence-polymerase chain reaction and 
karyotyping, with respective turnaround times of 1–2 days 
and 5 days.23 These investigations are crucial where there is 
uncertainty about sex assignment but also are an important 
guide for management where phenotypic sex is apparent. Sex 
chromosome DSD may be identified when a karyotype is per-
formed and in this situation it is diagnostic in itself, obviating 
the need for further molecular analysis. The most common 
sex chromosome DSD is Turner syndrome (45,X) followed 
by Klinefelter syndrome (47,XXY) and, less commonly, 
other forms of sex chromosome mosaicism may be identi-
fied. In the latter situation, a karyotype of genital or other 
tissue may be useful, or further analysis performed, to detect 
the presence of Y chromosome material. Prenatal studies 
consistently show that the majority of fetuses with confirmed 
45,X/46,XY mosaicism are phenotypically normal at birth.27 
A proportion of these may be at risk of late-onset “Turner 
syndrome-like” sequelae. However, there is no correlation 
between the severity of phenotype and the ratio of 45,X and 
46,XY cell lines in the blood.28 Small supernumerary marker 
chromosomes (sSMC) can be associated with a normal 
karyotype but also with a Turner syndrome karyotype (mos 
45,X/46,X,+mar). The majority of these sSMC are derived 
from sex chromosomes, generally either sSMC(X) ring or 
sSMC(Y), inverted duplication/isodicentric chromosomes.29 
However, their exact chromosome break points are rarely 
defined. Future more precise characterization of sSMC(X) 
or sSMC(Y) using molecular cytogenetic techniques may 
provide greater understanding of their cause and effect.
Detailed chromosome analysis using array comparative 
genomic hybridization (aCGH) allows the identification of 
microdeletions or microduplications, below the threshold of 
visibility by standard karyotype analysis (5 Mb) and is now 
widely available in optimally resourced centers. As standard 
practice, the routine genetic investigation of learning dis-
ability now includes aCGH, with a 15% rate of identification 
of a clinically significant microdeletion or microduplication. 
It is now recognized that in syndromic and non-syndromic 
DSD, recurrent, clinically significant regions of copy number 
variation (CNV) may be found in approximately a fifth of 
individuals.30 In 46,XX DSD due to disorders of Müllerian 
development, aCGH variations may be present in over a 
quarter of the cases.31 Furthermore, specific genomic regions 
of CNV may correlate with atypical genitalia, cryptorchid-
ism, and hypospadias. These regions of CNV may be de 
novo, occurring as a new event in the affected individual, or 
may be inherited and thus have implications for parents with 
regard to future recurrence risk and for the wider  family. It 
is recognized that the variable phenotype associated with 
certain DSD genes, such as NR5A1, explains why a region 
of CNV spanning this gene may be inherited from an appar-
ently unaffected mother who in fact had premature ovarian 
failure.32
The identification of novel genes involved in DSD as well 
as insight into developmental mechanisms may be facilitated 
using aCGH. For instance, investigation of individuals with 
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myotubular myopathy and 46,XY DSD with this technique 
led to the identification of a commonly deleted region, which 
spanned a single gene, MAMLD1 (CXorf6).33 Subsequently, 
nonsense mutations have been identified in Japanese boys 
with penoscrotal hypospadias and further studies have con-
firmed that mutation of MAMLD1 may contribute to a small 
proportion of 46,XY DSD.34
Traditional methods of molecular investigation of DSD 
include Sanger sequencing, often combined with multiplex 
ligation-dependent probe amplification to identify abnor-
malities in the dosage of a gene, such as a gene deletion 
or duplication. Investigation of 46,XY males would often 
include stepwise analysis of the AR gene, with mutations 
detected in approximately 30% of individuals with partial 
androgen insensitivity syndrome (PAIS), followed by SRY 
and NR5A1 testing in individuals with gonadal dysgenesis.35,36 
Mutations in MAMLD1, HSD17B3, and SRD5A2 and duplica-
tion of DAX1 are likely to account for a smaller proportion 
(5%–10%) of molecular diagnoses but their relative contribu-
tions to 46,XY DSD is less clear. The investigation of 46,XY 
DSD females (mostly AIS) is clearer, with mutations in the 
AR gene found in over 80% of individuals.35 Similar tech-
niques remain the mainstay of investigation of 46,XX DSD 
females, of whom the majority have CAH due to compound 
heterozygous, or homozygous, mutations in CYP21A2 gene.37 
Such a stepwise approach to genetic analysis in a combination 
of people with 46,XY and 46,XX DSD is reported to reveal 
a genetic alteration, including chromosomal rearrangement 
and gene mutations, in 64% of cases.38
The heterogeneous nature, particularly of XY DSD, 
has led to the grouping of genes into panels that can still 
be analyzed by these traditional methods. Advances in 
genetic technology, however, combined with an improved 
understanding of the complex network of genes involved in 
gonadal development, have led to the use of next genera-
tion sequencing (NGS) to permit more rapid analysis of a 
larger number of genes. Compared to standard fluorescent 
dideoxynucleotide Sanger sequencing, NGS, also known as 
massively parallel sequencing, permits at least 1,000 times 
more DNA sequence to be analyzed per run, in the diagnostic 
laboratory. The technology is advancing extremely rapidly, 
with regard to both the machines and the sequencing chem-
istry that can be used.39 The advantages and limitations of 
NGS and of other types of genetic analysis are summarized 
in Table 1.
At the present time, there are several different forms of 
NGS technologies. Two of the most popular technologies in 
the UK are the so-called Ion Semiconductor method used by 
the Life Technologies machines (including the Ion Torrent 
PGM and the Ion Proton) and the method utilized by Illu-
mina (in the MiSeq, NextSeq 500, HiSeq 2500, and HiSeq 
X machines). The Life Technologies method detects the pH 
changes that result from the release of individual protons 
upon the addition of individual nucleotides. In contrast, the 
Illumina method employs fluorescence analysis as its means 
of detecting nucleotide addition. It is, in fact, Illumina that 
is providing the DNA sequencing for the 100,000 Genomes 
Project of Genomics England.
Detection of sequence changes within a set or panel of 
many DSD-related genes could be achieved by pre-selecting 
DNA sequences (by using a customized hybridization 
method or by a custom-designed multiplex polymerase chain 
 reaction). This pre-selection approach is at present the most 
commonly used strategy in UK diagnostic laboratories for 
NGS of gene panels. An alternative approach is to conduct 
whole genome or whole exome sequencing and then to use 
bioinformatic selection of the regions of DNA sequence that 
are related to the set of genes of interest (ie, the target genes). 
This could be done in two or more stages: for example ana-
lyzing an initial set of the most commonly involved genes 
and then, if no pathogenic is detected, analyzing a wider set 
of genes, thus minimizing the number of detected variants 
of uncertain significance (Tables 2 and 3).
At present, unfortunately, while whole genome sequenc-
ing provides the most even coverage of the gene sequences 
(ie, with least likelihood of excluding gene sequences of 
interest) and is being used in a number of research labora-
tories worldwide, this approach is currently generally too 
costly for routine diagnostic purposes. Moreover, the clinical 
significance of variants located within approximately 98% of 
the genome is currently generally uninterpretable, although 
the ongoing international ENCODE project (ENCODE; 
encyclopedia of DNA elements) may clarify the significance 
of non-coding regions of the genome in the future.40
In research laboratories, NGS by whole exome or 
whole genome sequencing can provide not only the means 
by which to detect mutations within a large set of known 
DSD-related genes simultaneously, but also to identify new 
causative genes. In clinical diagnostic laboratories, how-
ever, the pre-selected gene set (or gene panel) approach is 
currently most widely utilized in the UK for the simultane-
ous mutation analysis of multiple genes. A recent report of 
an exome sequencing approach with filters for a large set 
of 64 genes known to be associated with a DSD, revealed 
an abnormality in about 30% of cases of 46,XY DSD41 
whereas the stepwise sequencing approach using a limited 
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Table 2 Primary list of DSD-related genes for simultaneous 
mutation analysis
Gene OMIM  
number
Associated phenotype
Investigation of XY DSD
AR 300068 Androgen insensitivity syndrome
SRY 400044 46,XX testicular DSD; 46,XY ovarian DSD
NR5A1 612965 46,XY sex reversal; XX premature ovarian 
failure
SRD5A2 264600 Steroid 5-AR deficiency
HSD17B3 264300 17β hydroxysteroid dehydrogenase iii  
deficiency
MAMLD1 300120 Hypospadias
NROB1 300018 46,XY sex reversal
Investigation of XX DSD
CYP21A2 201910 21-hydroxylase deficiency
Abbreviations: OMiM, Online Mendelian inheritance in Man; DSD, disorders of 
sex development. 
Table 3 extensive panel of DSD-related genes for simultaneous 
mutation analysis, if no pathogenic variants are detected from the 
primary list of genes
Gene OMIM  
number
Associated phenotype
WT1 607102 wilms tumor-aniridia-genital anomalies- 
retardation (WAGR); Denys-Drash syndrome
DMRT1 602424 46,XY gonadal dysgenesis
MAP3K1 600982 46,XY sex reversal
WWOX 605131 46,XY gonadal dysgenesis
SOX9 608160 46,XX sex reversal and campomelic dysplasia
CBX2 613080 46,XY sex reversal
DHH 605423 46,XY partial or complete gonadal dysgenesis
GATA4 600576 46,XY ambiguous genitalia
SOX3 300833 46,XX sex reversal and X-linked  
panhypopituitarism
RSPO1 609595 46,XX sex reversal and palmoplantar  
hyperkeratosis
FOXL2 605597 Blepharophimosis, ptosis and epicanthus  
inversus
TSPYL1 604714 Sudden infant death with testicular  
dysgenesis
ARX 300382 X-linked lissencephaly with ambiguous  
genitalia (XLAG)
POR 124015 Cytochrome P450 oxidoreductase deficiency
ATRX 300032 Alpha-thalassemia X-linked intellectual  
disability syndrome
DHCR7 270400 Smith-Lemli-Opitz syndrome (SLO)
HOXA13 142959 Hand-foot-uterus syndrome
LHCGR 152790 Leydig cell hypoplasia
AKR1C2 614279 46,XY sex reversal
BMP4 112262 Microphthalmia, pituitary anomalies  
and abnormal external genitalia
INSL3 146738 46,XY DSD, cryptorchidism
LGR8 606655 46,XY DSD, cryptorchidism
AMH 261550 Persistent Müllerian Duct Syndrome (PMDS)
AMHR2 261550 Persistent Müllerian Duct Syndrome
STAR 600617 Cholesterol desmolase-deficient CAH
HSD3B2 613890 3-beta hydroxysteroid dehydrogenase  
deficiency
CYP17A1 609300 17-alpha hydroxylase deficient CAH
CYP11B1 610613 11-beta hydroxylase deficient CAH
CYP19A1 107910 Aromatase deficient CAH
CYP11A1 118485 Adrenal insufficiency with 46,XY sex reversal
Abbreviations: OMiM, Online Mendelian inheritance in Man; DSD, disorders of 
sex development; CAH, congenital adrenal hyperplasia.
panel of nine genes identified an abnormality in 65% of 
cases of 46,XY DSD.38 It is possible that the reported 
diagnostic yield may depend on the clinical approach that 
is utilized, but there is a need to clearly understand the 
health as well as economic benefit of these two different 
approaches.
Despite the power of NGS, there are nevertheless 
several obstacles that usually require to be overcome in 
a diagnostic laboratory, prior to the introduction of NGS 
methodology.39 These include the purchase of expensive 
equipment and information technology infrastructure that 
can process and store enormous data files (eg, FastQ files) 
and the acquisition of bioinformatics expertise. A data 
analysis pipeline must be generated that is able to reliably 
map the millions of sequence reads to the genome, identify 
sequence variants, and then filter and extract a small num-
ber of likely pathogenic mutations from a very large dataset 
of detected sequence variants. A particular challenge is 
the determination of pathogenicity of missense mutations 
(amino acid substitutions), despite a range of available 
computer algorithms for this purpose. These include not 
only the popular SIFT and Polyphen2 algorithms but 
also Align-GVGD, MutPred, nsSNPAnalyzer, Panther, 
PhD-SNP, SNAP, and SNPs&GO.39 A further challenge is 
deciding upon the extent of variant information that should 
be reported to the patients themselves, although this is cur-
rently being addressed by wide discussion and by published 
European and US guidelines.42 Finally, it is important 
that, for clinical reporting of mutations, there is a multi-
disciplinary group (including laboratory scientists and 
experienced clinicians with specialized knowledge) who 
together can assess the significance of detected variants, 
in conjunction with available detailed clinical phenotypic 
and biochemical data.41
Increasing economic constraints on health spending 
generates a necessity to justify the clinical utility of inves-
tigation of affected individuals. Newer technologies are 
becoming more affordable but, even where available, at 
present their expense may restrict their wider application. 
In developed countries, obtaining a molecular diagnosis 
for a DSD is still only possible in less than half of affected 
individuals. Genomic or exomic sequencing therefore, offers 
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the  opportunity to identify additional genes and mechanisms 
associated with the development of these conditions, to 
improve diagnostic rates and, ultimately, to have a positive 
impact on management.
Current and emerging  
therapies – ethical challenges
Optimal care for infants and adolescents with DSD requires 
an experienced multidisciplinary team. The team should 
include specialists in endocrinology, surgery and/or urol-
ogy, clinical psychology/psychiatry, radiology, nursing, and 
neonatology. For infants with suspected DSD, this team has 
a role in providing patients and parents with information 
regarding diagnosis, sex assignment, and treatment options. 
In addition, the clinical team should have links to a wider 
multidisciplinary team that consists of specialists from adult 
endocrinology, plastic surgery, gynecology, clinical genet-
ics, clinical biochemistry, adult clinical psychology and 
social work and, if possible, also links to a clinical ethics 
forum.26
The presence at birth of a congenital anomaly affecting a 
child’s genital appearance or future fertility potential is chal-
lenging for both parents and health care providers. Shortly 
after birth major decisions are made, including sex assign-
ment and genital surgery, without knowledge of orientation, 
interests, or needs of the future adolescent and adult. The 
decisions taken are most of the time irreversible while, at the 
same time, interfering in highly sensitive domains, affecting 
reproduction, sexuality, physical and mental integrity, and the 
formation of a person’s self-identity.43,44
The Chicago Consensus of 2005 stated that sex assign-
ment cannot solely be based on genital appearance but should 
include consideration of the diagnosis, surgical options, need 
for lifelong replacement therapy, the potential for fertility, 
views of the family, and circumstances relating to cultural 
practices.20 Although karyotype and external appearance of 
genitalia continue to be associated with the choice of assigned 
sex,45 the results from a recent analysis of the International 
DSD (I-DSD) Registry revealed that the practice of assign-
ing male sex in newborns with 46,XY DSD seems to be 
increasing.46 This change in practice may be influenced by 
improvements in long-term surgical outcome in men with 
46,XY DSD with conditions such as micropenis and potential 
for penile reconstruction or neophallus construction.47,48 The 
knowledge of current trends in the practice of sex assign-
ment increases the necessity for improving the knowledge 
about the genetic etiology in 46,XY DSD. In addition, it has 
implications for the long-term management of domains such 
as hypogonadism, subfertility, gonadal tumorigenesis, sexual 
function, gender identity, and quality of life. It is also possible 
that there may be more cases of complex hypospadias and 
micropenis that may require expert input for reconstructive 
surgery later in life.46,48,49
It is likely that practice has also been influenced by those 
cases of XY DSD who were raised as girls and who developed 
gender dysphoria. Gender identity shows fluidity among 
persons born with PAIS, 5-AR deficiency and 17β-HSD3 
deficiency.43,50 Testosterone influences the development of 
a male gender role and probably increases the chance of a 
male gender identity development. However, even in cir-
cumstances in which the person has been prenatally exposed 
to high levels of testosterone and reared as girl from birth, 
a female adult gender identity is the rule rather than the 
exception.51 Psychosexual outcomes in DSD have been most 
extensively studied in 46,XX individuals with CAH.52 The 
vast majority of those raised as girls develop and maintain 
a female gender identity.53 However, a less strong female 
identification and gender dysphoria are more common in 
this group than in women without CAH51,54–56 and this may 
affect their quality of life.57
Early management in DSD has been based on the need 
to establish sex of rearing. Thereafter, medical and surgi-
cal treatment has been used to reinforce this decision. 
Feminizing surgery comprises clitoroplasty, labioplasty, 
and vaginoplasty. It is performed to allow menstrual flow, 
permit vaginal intercourse, and achieve a pleasing cosmetic 
result.58 The current recommendation suggests for restriction 
of genital surgery to those girls with severe masculinization 
of the external genitalia.20,59
There is no evidence to determine the best timing for 
clitoral reduction or vaginoplasty and there are no long-term 
studies comparing the functional, cosmetic, and psychological 
outcomes of early versus delayed (after puberty) reconstructive 
surgery. Some parents may consider early genital surgery as a 
mechanism that could protect their child from the risk of future 
stigma, however a thorough discussion of the controversies 
around undertaking or withholding early genital surgery is 
imperative in informing decisions.26,44 Supporting evidence 
for early surgery suggests that high rates of stress in mothers, 
social stigmatization, and isolation of the child and adverse 
psychosexual development could be avoided by early surgical 
treatment.58,60,61 Women, who had undergone surgery, when 
asked about the optimal timing of surgery, preferred scheduling 
the feminizing procedure in early childhood.62–64
On the other hand, altered physical sex development does 
not usually represent a surgical emergency for newborns. 
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Psychological support to parents being given the diagnosis of 
DSD to their newly born child may be more important than 
discussing surgical procedures with them. These conditions 
present significant parenting stress and reduced adaptive cop-
ing capacity, irrespective of the degree of genital ambiguity.65 
It is unclear whether surgical correction of atypical external 
genitalia is necessary or sufficient for well-being; quality of 
life, particularly with respect to sexual function, also needs 
to be taken into account.44 Damage of the neuronal network 
is reported to be highly likely in clitoral reduction, despite 
improvement in surgical technique, thus affecting sexual 
function in adult life.66–69 The cosmetic result in adulthood 
is also influenced by changes during puberty, including 
pubic hair and labial fat development. In the case of CAH, 
steroid replacement may induce reduction of the clitoris 
after a few months of treatment. Vaginal dilation is first 
line therapy for the girls with vaginal hypoplasia to permit 
menstruation70 but can be deferred where there is no uterus, 
until such time that the girl is sexually active. Moreover, 
most surgical interventions are irreversible and may restrict 
later options for sex reversal. In conditions associated with 
significant risk of gender dysphoria early surgery may also 
compromise future options.
DSD is associated with increased risk for germ-cell can-
cer (GCC). GCC is more prevalent (30%–50%) in conditions 
associated with gonadal dysgenesis as compared to 46,XY 
disorders of hormone synthesis or action (,1%–15%), 
where testis development is normal.71–74 An abdominal or 
inguinal position of the gonads represents an additional risk 
factor.75 The informed decision of the parent/patient for 
performing gonadectomy is based on the GCC risk and the 
sex of rearing.76
In boys with partial gonadal dysgenesis, Leydig cell 
function may be sufficient for spontaneous pubertal devel-
opment77–79 and, therefore, the current practice is to leave 
the gonads in place. In view of the increased risk of GCC in 
undescended testes, laparoscopy and early orchidopexy is 
performed at 6–12 months of age allowing for regular pal-
pation, ultrasound, and biopsy. In girls with partial gonadal 
dysgenesis, the possibility of androgen production during 
puberty, the expected infertility and the high risk of GCC, 
usually lead to the decision of gonadectomy during early or 
late childhood.76
Although past practice was the prophylactic removal of 
the gonads in females with complete androgen insensitivity 
syndrome (CAIS) as soon as the diagnosis is confirmed, it is 
more common now, as in PAIS, to leave the gonads in place 
until puberty is complete, because it allows  spontaneous 
pubertal development without estrogen replacement 
and allows the adolescent to be involved in the discus-
sions around surgery. Given the practice of prophylactic 
 gonadectomy in most cases in the past, data on GCC risk 
in adults are still  lacking, but have been estimated to range 
from 0.8%–22%.71
A small group of adult women with CAIS choose to 
retain their gonads after puberty, despite the malignancy 
risk, avoiding surgery and life-long replacement therapy and 
also raising the possibility, in light of advances in fertility 
treatment, of preservation of fertility potential.80 The testes 
in AIS are structurally normal, and spermatogonia have 
been reported in resected testes in several series, though 
they pose an uncertain fertility potential.81,82 The difficulty 
with conserving intra-abdominal gonads is that there are no 
available reliable screening tests that detect early malignant 
change. Understanding the molecular etiology underlying 
normal gonadal development allowed the development of 
markers to estimate the risk for GCC.76 It is expected that, 
with increased accessibility of diagnostic facilities, and with 
more children with these conditions being raised as males, 
additional data will become available in the future.
The increasing knowledge about sex determination and 
differentiation and modern society’s decreasing rigidity about 
the nature of sexual identity and gender roles have led to a 
thorough reappraisal of former treatment practice in DSD. 
Involving patient support groups in the assessment of medical 
interventions and seeking for more evidence on the long-term 
outcome of quality of life are both essential.44,83 The children 
should participate in decisions that affect them now or later 
and they should be comprehensively informed about their 
condition.57 Children who are informed and educated about 
their condition will have better opportunities to develop 
adaptive coping skills, including development of a positive 
self-image and expectations for a fulfilling adult life.
Future directions
Registries and data sharing
Given that discrete conditions that are associated with DSD 
are all very rare, meaningful research into these rare condi-
tions that has led to major evidence-based changes in clinical 
practice are limited. Following the Chicago Consensus in 
2005, which highlighted the need for greater data sharing 
across geographical boundaries, a group of experts created 
a web-based registry which was initially funded by the Euro-
pean Society for Paediatric Endocrinology and a European 
Union (EU) 7th Framework grant (EuroDSD) and is currently 
supported by the Medical Research Council of the UK as 
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the I-DSD Registry (http://www.i-dsd.org). This registry has 
users from 47 countries from all six habitable continents. Of 
these countries, there are 37 centers that have entered almost 
1,500 cases. The registry also supports the development of 
new modules, as it is currently undertaking for EU-TAIN 
(Treatment for adrenal insufficiency in neonates and infants; 
http://www.tain-project.org), another EU funded project. 
Through its standardized collection of data, the registry has 
the ability to perform conclusive secondary research46,84 and 
has the potential to act as a gateway to a virtual research 
environment that integrates other datasets and paves the way 
to primary research. To maximize stakeholder involvement, 
the registry has recently introduced the option for participants 
to access some of the data that have been entered on them 
by their clinicians. It is likely that greater involvement of 
these patient participants in the I-DSD Registry will lead to 
more patient-focused research as well as an improved wider 
understanding of complex research questions.
Networks of clinical  
and research expertise
Although many centers manage conditions such as DSD 
through a multidisciplinary team, it is increasingly realized 
that such expertise is not available at many centers and there 
is a need to throw the net wider. Registries such as I-DSD 
are not simply a virtual biobank of data on people with DSD, 
but are also a registry of experts who manage a range of rare 
conditions. Thus, a rare disease registry can also facilitate 
the development of a virtual network of clinical and research 
expertise. There is a need for formal networks at several 
levels. Recently, the European Cooperation of Science and 
Technology has funded the development of a network of 
clinical researchers, scientists, and patient groups (DSDnet; 
http://www.dsdnet.eu). It is anticipated that this formal net-
work will lay down the framework as well as the priorities for 
research that needs to be performed over the next decade. It is 
also anticipated that this body will also define the standards 
of care that should be maintained in centers of expertise in 
DSD. Thus, it is possible that DSDnet evolves into a European 
reference network for DSD that relies on the I-DSD Registry 
for data curation as well as dissemination of information to a 
wider international as well as a virtual network of clinicians, 
scientists as well as patients and participants.
Handling complex genetic information
With increasing availability of complex genetic analyses 
including aCGH, NGS as well as whole exome and genome 
sequencing, many patients will undergo these analyses. 
With the increasing complexity of genetic and bioinformatic 
analysis and the greater emphasis and requirement for clear 
communication with patients and carers, it is likely that the 
diagnostic and prognostic genetic pathway that starts and ends 
with the patients will require a wider group of experts. A DSD 
diagnostic group such as that described recently41 or created 
by the Scottish DSD Network (http://www.sdsd.scot.nhs.uk) 
and which consists of pediatric endocrinologists, clinical and 
molecular geneticists and steroid biochemists, who have links 
to bioinformatic support, will become increasingly routine. 
In cases where there is uncertainty at a regional level, there 
is a need for the international DSD community to develop 
a panel of experts that can advise and assist. This requires 
a new way of working and a level of collaboration that has 
not previously existed in the field of DSD. However, given 
the experience of recent initiatives such as I-DSD, DSDnet, 
and the DSD Working Group of the European Society for 
Paediatric Endocrinology (http://www.eurospe.org) it is likely 
that this will succeed. These networks need to extend and 
include the wider community of scientists so that new cost 
efficient but reliable tools can be developed for functional 
confirmation of novel genetic variants that have not been 
previously linked to a DSD phenotype.
Transcriptomics and its potential  
to clarify the phenotype
One of the major findings of projects such as ENCODE40 was 
that the human transcriptome is far larger and more complex 
than the genome, especially with the presence of alternative 
splicing of genes and the presence of thousands of non-coding 
ribonucleic acids (RNAs) that have the ability to modify 
RNA silencing and post-transcriptional regulation of gene 
expression. Sexual dimorphism of gene transcription is a very 
common phenomenon in the mammal and in the mouse and 
may affect two thirds of the transcriptome in some tissues.85 
Although it is possible that some of this sexual dimorphism 
is due to sex chromosome differences, it is possible that 
some of these differences are due to androgen effects. The 
presence of an androgen-dependent transcriptome has been 
identified in genital skin fibroblasts86 as well as peripheral 
blood mononuclear cells.87 An assessment of an androgen-
dependent transcriptome may be of benefit in a number of 
clinical scenarios but its translation into clinical practice will 
require major bioinformatic input.
imaging
In the past, most radiological research focused on improv-
ing the technical quality of imaging. However, substantial 
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advances in magnetic resonance spectroscopy, diffusion 
weighted imaging, dynamic contrast enhanced methods and 
radiochemistry means that cellular and molecular processes 
such as angiogenesis, apoptosis, signal transduction and 
metabolic pathways can now be imaged and this is already 
becoming increasingly routine in the management of andro-
gen dependent prostate cancer.88 The prospect of improving 
our understanding of the underlying pathology, linking it 
to the genetic variation and understanding the longitudinal 
evolution of the clinical phenotype as well as its response 
to therapy will advance considerably as these technologies 
become more accessible.
Health economic assessment  
of interventions in DSD
Rare diseases may pose a burden on the affected person 
and the family89 and whilst parents of children with DSD 
clearly report experiencing difficulties in coping,65 this has 
rarely been quantified. In addition, some affected people 
and their clinical and non-clinical carers may not necessarily 
consider the condition a disorder but simply a difference in 
development which does not have a bearing on day to day 
function. Given that in most cases, interventions involve 
surgical, medical, and psychological interventions with a 
limited evidence base, there is a need to understand the health 
economic benefit of these interventions. This assessment 
should also be extended to the use of new diagnostic and 
therapeutic technologies so that the clinical utility of these 
complex procedures can be quantified.
Conclusion
In conclusion, DSD represents a group of diverse, rare con-
ditions with a very wide phenotypic spectrum where a clear 
molecular genetic diagnosis remains elusive in the majority. 
These conditions pose multiple therapeutic challenges. It is 
likely that innovation in “omic” technologies will lead to 
improved understanding of the underlying abnormality as 
well as explain the variability in the phenotype. However, 
a real improvement in the health of those who are affected 
requires a change in practice of the scientific community 
so that data sharing in clinical practice and scientific 
endeavor becomes normal practice in this large group of 
rare conditions.
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